Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 3/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871039 | 1.00 | AOC3 (0.48) | AOC3SLC6A2SLC6A4CASRSLC22A1 | |
| SCHEMBL16871041 | 1.00 | AOC3 (0.48) | AOC3SLC6A2SLC6A4CASRSLC22A1 | |
| SCHEMBL15026291 | 1.00 | AOC3 (0.48) | AOC3SLC6A2SLC6A4CASRSLC22A1 | |
| SCHEMBL16871058 | 0.84 | CASR (0.43) | AOC3SLC6A2SLC6A4CASRL3MBTL1 | |
| SCHEMBL16871397 | 0.84 | CASR (0.43) | AOC3SLC6A2SLC6A4CASRL3MBTL1 | |
| SCHEMBL15026266 | 0.83 | KDM4E (0.44) | SLC22A1OPRM1HIF1ACYP2D6 | |
| SCHEMBL16871644 | 0.83 | AOC3 (0.44) | AOC3CASRL3MBTL1CHRM2CHRM1 | |
| SCHEMBL16871493 | 0.83 | AOC3 (0.44) | AOC3CASRL3MBTL1CHRM2CHRM1 | |
| SCHEMBL16871515 | 0.82 | CASR (0.47) | AOC3CASRMEN1KMT2A | |
| SCHEMBL16871322 | 0.82 | CASR (0.47) | AOC3CASRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183727-A1 | METHOD FOR THE PREPARATION OF 1-ARYL-1-ALKYL-2-ALKYL-3-DIALKYLAMINOPROPANE COMPOUNDS | SIEGFRIED AG (CH) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183727-A1 | METHOD FOR THE PREPARATION OF 1-ARYL-1-ALKYL-2-ALKYL-3-DIALKYLAMINOPROPANE COMPOUNDS | CYP3A43, CYP1A2, CYP2C8 | AOC3 124/4885SLC6A2 49/4885SLC6A4 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.